

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Brexpiprazole (Rexulti)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as 2 week period without clinically significant improvement in target symptoms or side effects related to dosage form that cannot be resolved by adjusting dose or timing
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **brexpiprazole (Rexulti)** will be covered on the prescription drug benefit when the following criteria are met:

Schizophrenia

- Prescriber is or has consulted with a mental health clinician
- Patient has a diagnosis of schizophrenia
- Patient is age 18 years or older
- Patient has failed an adequate trial^ or patient has an allergy or intolerance* to 2 formulary antipsychotic agents (e.g. quetiapine, risperidone, olanzapine, ziprasidone, lurasidone, clozapine, or a first-generation antipsychotic)
- Patient has failed an adequate trial^ or patient has an allergy or intolerance* to aripiprazole

Major Depressive Disorder (MDD)

- Prescriber is or has consulted with a mental health clinician
- Patient has a diagnosis of Major Depressive Disorder
- Patient is age 18 years or older
- Patient is currently taking an antidepressant (SSRI, SNRI, TCA, bupropion, mirtazapine)
- Patient has documented contraindication, intolerance, or treatment failure to at least 1 formulary options from the following medication classes: antidepressants and mood stabilizers (e.g. lithium or antiepileptic used for mood disorder such as divalproex)
- Patient has failed an adequate trial^ or patient has an allergy or intolerance* to 2 formulary antipsychotic agents (e.g. quetiapine, olanzapine, aripiprazole)

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Brexpiprazole (Rexulti)

Criteria for current or new Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **brexpiprazole (Rexulti)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has diagnosis of schizophrenia or major depressive disorder